End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
60.51 CNY | -0.31% | -6.43% | +15.59% |
22/04 | Xiamen Amoytop Biotech Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
18/03 | China Stocks Advance Over Positive Economic Data; Amoytop Biotech Rises 6% | MT |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- Analysts expect a sharply increasing business volume for the group, with high growth rates in the coming years.
- The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- For the past twelve months, EPS forecast has been revised upwards.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 32.75 times its estimated earnings per share for the ongoing year.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The company is not the most generous with respect to shareholders' compensation.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+15.59% | 3.41B | - | ||
-3.45% | 87.17B | A- | ||
+2.76% | 40.1B | A- | ||
-15.97% | 31.38B | B- | ||
+57.86% | 25.12B | A | ||
-15.61% | 15.59B | C | ||
-9.12% | 12B | D+ | ||
-42.56% | 11.8B | B | ||
-18.24% | 11.8B | B- | ||
+6.89% | 8.81B | B+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 688278 Stock
- Ratings Xiamen Amoytop Biotech Co., Ltd.